Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03275480
Recruiting Observational

Institut Paoli Calmettes Myelodysplastic Syndromes Database

NCT03275480 · tracked via the Priya Life Science France tracker
Sponsor
Institut Paoli-Calmettes
Phase
Observational
Started
2016-01-18
Last updated
2019-05-14

Condition(s) studied

Myelodysplastic Syndromes

Study summary

Database of Institut Paoli-Calmettes patients diagnosed with Myelodysplastic Syndromes

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient with a diagnosis of Myelodysplastic Syndromes Exclusion Criteria: * None

Primary outcome measure(s)

  • Survival of patients with myelodysplastic syndrome(MDS) — 10 years
    Overall survival of all patients with MDS who are taken in charge in Institut Paoli Calmettes Cancer Center

Trial sites (1)

FacilityCityRegionStatus
Institut Paoli-Calmettes Marseille PACA Recruiting

More Institut Paoli-Calmettes trials in France

Institut Paoli Calmettes Hepatic Surgery Database Recruiting
Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers Starting soon
Evaluation of the Efficacy of Duodenal Prostheses Not Covered Over 6 Years Recruiting
Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy Recruiting

Other trials for the same condition

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA Recruiting
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring Enrolling by invitation
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) Active, not recruiting
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes Active, not recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03275480 on ClinicalTrials.gov ↗ ← All trials in France